ClinicalTrials.gg
Drug

Sapropterin clinical trials

Also written Kuvan, Tetrahydrobiopterin and Phenoptin.

studies test it
62
open now
4
in phase 3
12
first study started
2004

How each study uses sapropterin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sapropterin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Dec 2007 · KUVAN · NDA 022181 (FDA, Drugs@FDA)
European Union
2 Dec 2008 · Kuvan · EMEA/H/C/000943 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sapropterin dihydrochloride
24
sapropterin
10
Tetrahydrobiopterin (BH4)
5
6R BH4
3
Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
2

Brand

Kuvan
31
Phenoptin
2

Other names

Tetrahydrobiopterin
13
BH4
9
6R-BH4
6

Studies by the year they started

61 studies that test it; most in 2011 (9)

Studies that test sapropterin, by start year
YearStudies
20042
20054
20065
20072
20085
20094
20106
20119
20123
20132
20141
20152
20162
20182
20191
20201
20213
20223
20242
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
14
Phase 2
27
Phase 3
12
Phase 4
5
No phase
9

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 18 · Other 44

BioMarin Pharmaceutical (15) · Emory University (4) · VA Office of Research and Development (3) · Augusta University (3) · The Children's Health Council (2) · Merck KGaA, Darmstadt, Germany (2) · The University of Texas Health Science Center, Houston (2) · West China Second University Hospital (2)

Often tested with

Tested in the same studies.

Ascorbic Acid (3) · Vitamin E (3) · Thioctic Acid (3) · Antioxidants (1) · Simvastatin (1) · Arginine (1) · Acetovanillone (1) · Allopurinol (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test sapropterin.

Studies

Open first, then newest update. How each study uses sapropterin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 62

See all 62 studies that test sapropterin →

Given beside what is tested · 4 — sapropterin is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call sapropterin · ClinicalTrials.gg INT002274

  • MeSH (NLM) C003402sapropterinOne source NLM
  • UNII (FDA) EGX657432ISAPROPTERINConfirmed FDA, NLM, Wikidata
  • RxNorm 753340One source FDA
  • Wikidata Q419808sapropterinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C78087SapropterinOne source FDA
  • DrugBank DB00360One source Wikidata

Also registered as 2,4,5-trihydroxybutyrophenone (UNII KN729W3LR0) and sapropterin dihydrochloride (UNII RG277LF5B3 · RxNorm 753341).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.